PHI FPX 3200 Assessment 2 Right to Experimental Drugs

Student name

Capella University

PHI-FPX3200

Professor Name

Submission Date

A Right to Experimental Drugs

The issue of morality is highlighted when it comes to the moral right of patients who have no other treatment avenue to use unapproved experimental drugs. Before these clinical trial drugs are administered to enrolled patients, the FDA has to approve these treatments (Largent et al., 2021). Routine raises doubts on the confidentiality of the autonomy of the patient and the risk of safety of untested drugs. This evaluation explores both sides of the argument concerning the evaluation of access to experimental drugs on the basis of critical ethical principles.

Ethical Theories and Moral Principles

The modern quandary is ensured with the help of Utilitarianism, Kantian Ethics, Ethics by Ross, and Natural Law Ethics, which become complementary standards of investigation. Utilitarianism allows the decision-makers to maximize happiness and reduce pain, particularly on the issues that widely affect the population and the way resources are allocated in healthcare (Yang, 2024).

Kantian Ethics is relevant to medical ethics since it offers fundamental moral rules on safeguarding the autonomy of patients and universal ethics, as well as honoring human dignity (Sullivan et al., 2021). The flexibility of Ethics by Ross lies in the fact that it recognizes ethical issues in healthcare when there are conflicting obligations, such as patient benefit and equitable care distribution (Hammerton, 2022).

Natural Law Ethics is an ethical theory that anchors its decision-making power like human beings to improve human welfare and applies to bioethics and especially genetic engineering (Magid, 2022). The theories collaborate in the problem of experimental drug access since, under the Utilitarianism theory, the benefit and harm analyses are carried out, in Kantian Ethics, the autonomy is preserved, and in the Ross Ethics, justice and beneficence are maintained in a proper balance.

Principle of Informed Consent Related to Issues

Informed consent of experimental drugs is part of medical ethics since the practice permits patients to choose medical care independently. This principle safeguards patients who do not receive any other treatment due to the elimination of coercion, making them realize that the drug is experimental medicine (Largent et al., 2021). Kantian ethics regulates that informed consent is an essential right of self-choice, and Utilitarian ethics is concerned with the maximum of positive outcomes.

The Ethics of Beneficence created by Ross and the informed consent are combined, and patient independence is at the heart of the Natural Law Ethics (Magid, 2022). Informed consent by healthcare providers is an act of defending the right of the patient to make a choice on his or her basic dignity.

Assumptions

This study starts with two preconditions: the initial one is that the patient has to comprehend medical knowledge, and the second, the patient must also have the appropriate capacity to formulate decisions based on this knowledge. This model relies on the healthcare providers who offer unbiased full-disclosure, along with the respect of patient choice (Largent et al., 2021). Reasoning relies on voluntary patient decisions, which are not accompanied by undue coercion or exploitation, particularly in cases with experimental treatment with unpredictable outcomes.

Costs and Benefits of Unapproved Experimental Drugs

The information on offering experimental drugs not yet approved by the regulatory bodies offers treatment options for patients who do not have a practical choice that would improve the outcome and keep the expectations positive. Nonetheless, the prices are high. Experimental drugs perform poorly or have unforeseen side effects that may put therapeutic participants at risk.

The post-payment access to experimental drugs has a negative impact on the clinical trial population and results in an inability to evaluate the safety and efficacy of a drug (Folkers et al., 2020). The issue of the compassionate access program raises different opinions since there are those who support the policy and others who caution that the policy will harm the scientific investigations and even make false assumptions that the drug is effective. It is the patient benefit assessment in the decision process, and ethical requirements such as safety through testing protocols.

Wider Pools of Patients

The provision of the pre-approved therapeutic drugs to additional groups of patients brings forth good merits and demerits. The advantages of expanding drug access are potentially life-saving for the patients, as they do not have any other treatment options (Yuan et al., 2024). Terminally ill people can receive medical services utilizing drugs that are effective in other similar illnesses, hence causing improvements in the quality of life and the duration of survival. Being distributed on a larger scale would allow generating additional real-world data regarding the drug efficacy in other groups of the population that would benefit all subsequent patients.

Concerns and Knowledge Gap

The safety issues intensify when additional preapproved medications are being made available because the most susceptible groups, like elderly individuals and patients with various ailments, may have unknown drug side effects that could not be identified during testing. The increased supply of pre-approved medications may present a challenge to healthcare organizations that will decrease access to care by the most needy patients (Yuan et al., 2024).

No conclusions are final as to the reaction of medicines outside the clinical investigation environment. The gap in knowledge concerns the way the medications act within the various patients. Further research is needed to establish these risks in order to be able to make effective decisions as to the distribution of medications.

Conclusion

Decision-making regarding access to experimental drugs and drugs approved by patient autonomy, safety, and fairness was passed. The experimental pharmaceuticals available to the patients in the hospital provide them with hope, but put them at risk of the side effects of the unknown drugs. The models given by Utilitarianism, Kantian Ethics, and the Ethics presented by Ross can be used as a decision-making tool, although there are knowledge gaps that scientists must address. The last stage of decision-making is the respect of the rights of the individuals and the needs of the population’s health and safety.

1st and 3rd Assessment for this class:  PHI FPX 3200 Assessment 1 and PHI FPX 3200 Assessment 3